The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.
2025
Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research
There is a positive association between melanoma and Parkinson’s disease (PD), with the risk for melanoma ranging between 1.4- and 20-fold among individuals with PD. The risk is bidirectional, too, because there is also a 1.7- to 4.2-fold increased risk for PD in patients with melanoma. The link between PD and melanoma is not well understood, but increased expression of the PD-associated protein alpha-synuclein (?Syn) in melanoma cells may provide insight into the positive association between the two diseases.
Study uncovers a way to boost treatment for aggressive melanoma
A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.
BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the treatment arm.